These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 431472)

  • 1. [Non-specific immune mechanisms. The alternate pathway in the complement system].
    Schön K; Koeppe HW
    Med Klin; 1979 Mar; 74(13):461-9. PubMed ID: 431472
    [No Abstract]   [Full Text] [Related]  

  • 2. [Complement: mechanisms of activation, functions, analysis].
    Dessaint JP; Wattre P; Santoro F; Capron A
    Lille Med; 1979; 24(7):551-8. PubMed ID: 397392
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
    Welch TR; Forristal J; Beischel L
    J Lab Clin Med; 1986 Jun; 107(6):529-33. PubMed ID: 3635565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 5. The biological role of the complement system and the clinical importance of complement measurements.
    Füst G
    Haematologia (Budap); 1978-1979; 12(1-4):85-106. PubMed ID: 395046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
    Lesavre P; Leibowitch J
    Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
    [No Abstract]   [Full Text] [Related]  

  • 7. Alternative pathway complement activation in rheumatoid arthritis.
    El-Ghobarey A; Whaley K
    J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of complement by autoimmune antibodies isolated from sera of patients with membranoproliferative glomerulonephritis and systemic lupus erythematosus.
    Daha MR; Van Es LA
    Neth J Med; 1982; 25(7):202-7. PubMed ID: 6924073
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
    Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
    Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complement: physiopathology, pharmacology and clinical aspects].
    Orrico A; Auteri A
    Ann Sclavo Collana Monogr; 1985; 2(1-2):3-146. PubMed ID: 3880494
    [No Abstract]   [Full Text] [Related]  

  • 11. [Progress in the knowledge of complement. II. Nephritic factors].
    Leibowitch J; Lesavre P
    Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
    [No Abstract]   [Full Text] [Related]  

  • 12. [The complement system].
    Lambert PH
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1180-4. PubMed ID: 1215899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
    Ekdahl KN; Nilsson B
    J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].
    Berthoux FC; Freyria AM
    Nephrologie; 1980; 1(2):61-6. PubMed ID: 7301022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection.
    Fearon DT; Austen KF
    N Engl J Med; 1980 Jul; 303(5):259-63. PubMed ID: 6900901
    [No Abstract]   [Full Text] [Related]  

  • 16. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
    Kazatchkine MD; Fearon DT; Austen KF
    J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
    [No Abstract]   [Full Text] [Related]  

  • 17. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement fixing properties of antibodies to double-stranded DNA in systemic lupus erythematosus.
    Gharavi AE; Elkon KB; Schifferli JA; Hughes GR
    J Clin Lab Immunol; 1981 Nov; 6(3):251-5. PubMed ID: 7338885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 20. [Complement, a system of recognition of activation and amplification].
    Peltier AP; Kazatchkine MD
    Ann Immunol (Paris); 1982; 133C(2):149-54. PubMed ID: 6921958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.